Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

42.70 +0.31 (+0.74%)

Delayed Quote Updated: 12:20 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Supernus Announces Third Quarter 2025 Financial Results

November 04, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2

November 03, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best...

Via StockStory

Topics Artificial Intelligence Intellectual Property

A Preview Of Supernus Pharmaceuticals's Earnings ↗

November 03, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 03, 2025

Via Benzinga

Supernus Pharmaceuticals (SUPN) Reports Q3: Everything You Need To Know Ahead Of Earnings

November 02, 2025

Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings this Tuesday after market hours. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

3 Cash-Producing Stocks That Fall Short

October 30, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Emerges as a Top Affordable Growth Candidate ↗

October 28, 2025

Supernus Pharmaceuticals (SUPN) offers affordable growth with strong EPS, solid financials, and a low P/E ratio, making it a compelling investment opportunity.

Via Chartmill

Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings) ↗

October 23, 2025

Via Benzinga

3 Small-Cap Stocks We’re Skeptical Of

October 23, 2025

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...

Via StockStory

Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

October 21, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

3 Stocks Under $50 We Steer Clear Of

October 20, 2025

The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to...

Via StockStory

SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Presents a Compelling Mix of Growth and Technical Momentum ↗

October 17, 2025

Supernus Pharmaceuticals (SUPN) is a strong growth stock with a debt-free balance sheet and a positive technical breakout pattern. Explore its potential.

Via Chartmill

Branded Pharmaceuticals Stocks Q2 Earnings Review: Supernus Pharmaceuticals (NASDAQ:SUPN) Shines

October 12, 2025

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Supernus Pharmaceuticals (NASDAQ:SUPN)...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Supernus Pharmaceuticals (SUPN) Stock Is Up, What You Need To Know

October 09, 2025

Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 4.6% in the morning session after Piper Sandler upgraded the company's stock from a "Neutral" to an "Overweight"...

Via StockStory

Topics Artificial Intelligence

Crowdstrike To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday ↗

October 09, 2025

Via Benzinga

Q2 Earnings Highs And Lows: Organon (NYSE:OGN) Vs The Rest Of The Branded Pharmaceuticals Stocks

October 08, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst...

Via StockStory

Topics Artificial Intelligence Intellectual Property

SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Represents an Affordable Growth Opportunity ↗

October 07, 2025

Supernus Pharmaceuticals (SUPN) offers affordable growth with strong earnings, a clean balance sheet, and an attractive P/E ratio below industry peers.

Via Chartmill

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

The U.S. pharmaceutical industry is at the center of a policy maelstrom.

Via Benzinga

Topics ETFs

Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL)

September 24, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe

September 17, 2025

From Biogen Inc.

Via GlobeNewswire

3 Overrated Stocks with Questionable Fundamentals

September 08, 2025

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Via StockStory

SUPERNUS PHARMACEUTICALS INC (NASDAQ:SUPN) Emerges as a Top Affordable Growth Stock ↗

September 08, 2025

SUPERNUS (SUPN) offers affordable growth with strong EPS & revenue expansion, solid profitability, and a sound financial base, all at a discount to the pharmaceutical industry.

Via Chartmill

Unpacking Q2 Earnings: Eli Lilly (NYSE:LLY) In The Context Of Other Branded Pharmaceuticals Stocks

September 07, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Eli Lilly (NYSE:LLY) and the best and worst...

Via StockStory

Topics Artificial Intelligence Intellectual Property

1 Cash-Producing Stock to Research Further and 2 We Brush Off

September 05, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Unpacking Q2 Earnings: Elanco (NYSE:ELAN) In The Context Of Other Pharmaceuticals Stocks

September 01, 2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Elanco (NYSE:ELAN) and the best and worst...

Via StockStory

Topics Artificial Intelligence Intellectual Property

2 Healthcare Stocks on Our Watchlist and 1 We Avoid

September 01, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID...

Via StockStory

Topics Stocks

Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q2

August 27, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at branded pharmaceuticals stocks, starting...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Supernus Pharmaceuticals to Participate in September Investor Conferences

August 27, 2025

From Supernus Pharmaceuticals, Inc.

Via GlobeNewswire

Branded Pharmaceuticals Stocks Q2 Recap: Benchmarking Bristol-Myers Squibb (NYSE:BMY)

August 26, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Bristol-Myers Squibb (NYSE:BMY) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.